Principal Financial Group Inc Paratek Pharmaceuticals, Inc. Transaction History

Principal Financial Group Inc

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 10, 2022	SELL	$1.73 - $3.09 $11,052 - $19,742	-6,389 Reduced 19.19%	26,912 $52,000
Q1 2022 May 09, 2022	SELL	$2.94 - $4.77 $49,730 - $80,684	-16,915 Reduced 33.68%	33,301 $99,000
Q4 2021 Feb 09, 2022	SELL	$4.07 - $5.3 $22,148 - $28,842	-5,442 Reduced 9.78%	50,216 $225,000
Q3 2021 Nov 09, 2021	SELL	$4.7 - $7.24 $209,267 - $322,361	-44,525 Reduced 44.44%	55,658 $271,000
Q2 2021 Aug 10, 2021	BUY	$6.81 - $10.93 $682,246 - $1.1 Million	100,183 New	100,183 $683,000
Q1 2021 May 10, 2021	SELL	$6.14 - $8.31 $64,525 - $87,329	-10,509 Closed	0 $0
Q4 2020 Feb 08, 2021	BUY	$4.58 - $7.14 $48,131 - $75,034	10,509 New	10,509 $66,000

1.54M

Ticker PRTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 54,862,500
Description
Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectru...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.